ZA202301635B - Ham15-52 analogues with improved amylin receptor (hamy3r) potency - Google Patents
Ham15-52 analogues with improved amylin receptor (hamy3r) potencyInfo
- Publication number
- ZA202301635B ZA202301635B ZA2023/01635A ZA202301635A ZA202301635B ZA 202301635 B ZA202301635 B ZA 202301635B ZA 2023/01635 A ZA2023/01635 A ZA 2023/01635A ZA 202301635 A ZA202301635 A ZA 202301635A ZA 202301635 B ZA202301635 B ZA 202301635B
- Authority
- ZA
- South Africa
- Prior art keywords
- ham15
- hamy3r
- analogues
- amylin receptor
- potency
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20198117 | 2020-09-24 | ||
| PCT/EP2021/076250 WO2022063925A1 (en) | 2020-09-24 | 2021-09-23 | Ham15-52 analogues with improved amylin receptor (hamy3r) potency |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202301635B true ZA202301635B (en) | 2024-03-27 |
Family
ID=72659001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2023/01635A ZA202301635B (en) | 2020-09-24 | 2023-02-09 | Ham15-52 analogues with improved amylin receptor (hamy3r) potency |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US12139520B2 (https=) |
| EP (1) | EP4021929B1 (https=) |
| JP (1) | JP2023544959A (https=) |
| KR (1) | KR20230073176A (https=) |
| CN (1) | CN116322741A (https=) |
| AU (1) | AU2021350396A1 (https=) |
| BR (1) | BR112023002525A2 (https=) |
| CA (1) | CA3189267A1 (https=) |
| DK (1) | DK4021929T5 (https=) |
| ES (1) | ES2950137T3 (https=) |
| FI (1) | FI4021929T3 (https=) |
| HR (1) | HRP20230534T1 (https=) |
| HU (1) | HUE062560T2 (https=) |
| IL (1) | IL300620B2 (https=) |
| MX (1) | MX2023002182A (https=) |
| PL (1) | PL4021929T3 (https=) |
| PT (1) | PT4021929T (https=) |
| RS (1) | RS64256B1 (https=) |
| SI (1) | SI4021929T1 (https=) |
| WO (1) | WO2022063925A1 (https=) |
| ZA (1) | ZA202301635B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI815327B (zh) | 2021-03-03 | 2023-09-11 | 美商美國禮來大藥廠 | 長效澱粉素受體促效劑及其用途 |
| IL317600B2 (en) | 2022-07-01 | 2026-03-01 | Gubra As | Amylin receptor (HAMY3R) agonists with improved chemical stability |
| TW202540155A (zh) | 2023-11-30 | 2025-10-16 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1、gip及澱粉素受體之三重促效劑 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5288931A (en) * | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
| GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
| FI117667B (fi) * | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
| NZ579621A (en) * | 2004-02-11 | 2011-03-31 | Amylin Pharmaceuticals Inc | Hybrid polypeptides with selectable properties |
| WO2007022123A2 (en) | 2005-08-11 | 2007-02-22 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
| AU2012212047A1 (en) * | 2011-02-03 | 2013-08-22 | Xoma Technology Ltd. | Methods and materials for enhancing functional protein expression in bacteria |
| JP6121992B2 (ja) | 2011-06-10 | 2017-04-26 | ノヴォ ノルディスク アー／エス | ポリペプチド |
| AR097701A1 (es) * | 2013-09-19 | 2016-04-13 | Zealand Pharma As | Análogos de amilina |
| BR112017019378A2 (pt) | 2015-03-18 | 2019-02-19 | Zealand Pharma A/S | análogos de amilina |
| WO2019005623A1 (en) | 2017-06-30 | 2019-01-03 | Adepthera Llc | PEPTIDE ANALOGS |
| AR116632A1 (es) | 2018-10-11 | 2021-05-26 | Intarcia Therapeutics Inc | Polipéptidos análogos de la amilina humana y sus métodos de uso |
-
2021
- 2021-09-23 FI FIEP21782735.1T patent/FI4021929T3/fi active
- 2021-09-23 WO PCT/EP2021/076250 patent/WO2022063925A1/en not_active Ceased
- 2021-09-23 JP JP2023510390A patent/JP2023544959A/ja active Pending
- 2021-09-23 RS RS20230442A patent/RS64256B1/sr unknown
- 2021-09-23 ES ES21782735T patent/ES2950137T3/es active Active
- 2021-09-23 CN CN202180056599.9A patent/CN116322741A/zh active Pending
- 2021-09-23 HR HRP20230534TT patent/HRP20230534T1/hr unknown
- 2021-09-23 AU AU2021350396A patent/AU2021350396A1/en active Pending
- 2021-09-23 DK DK21782735.1T patent/DK4021929T5/da active
- 2021-09-23 EP EP21782735.1A patent/EP4021929B1/en active Active
- 2021-09-23 CA CA3189267A patent/CA3189267A1/en active Pending
- 2021-09-23 US US18/024,879 patent/US12139520B2/en active Active
- 2021-09-23 MX MX2023002182A patent/MX2023002182A/es unknown
- 2021-09-23 PL PL21782735.1T patent/PL4021929T3/pl unknown
- 2021-09-23 HU HUE21782735A patent/HUE062560T2/hu unknown
- 2021-09-23 IL IL300620A patent/IL300620B2/en unknown
- 2021-09-23 PT PT217827351T patent/PT4021929T/pt unknown
- 2021-09-23 KR KR1020237005061A patent/KR20230073176A/ko active Pending
- 2021-09-23 BR BR112023002525A patent/BR112023002525A2/pt unknown
- 2021-09-23 SI SI202130047T patent/SI4021929T1/sl unknown
-
2023
- 2023-02-09 ZA ZA2023/01635A patent/ZA202301635B/en unknown
-
2024
- 2024-10-10 US US18/911,605 patent/US20250129134A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3189267A1 (en) | 2022-03-31 |
| AU2021350396A1 (en) | 2023-03-16 |
| CN116322741A (zh) | 2023-06-23 |
| IL300620B2 (en) | 2025-12-01 |
| IL300620A (en) | 2023-04-01 |
| JP2023544959A (ja) | 2023-10-26 |
| HRP20230534T1 (hr) | 2023-08-04 |
| BR112023002525A2 (pt) | 2023-04-04 |
| WO2022063925A1 (en) | 2022-03-31 |
| KR20230073176A (ko) | 2023-05-25 |
| HUE062560T2 (hu) | 2023-11-28 |
| RS64256B1 (sr) | 2023-07-31 |
| IL300620B1 (en) | 2025-08-01 |
| US20240101634A1 (en) | 2024-03-28 |
| PL4021929T3 (pl) | 2023-07-31 |
| FI4021929T3 (fi) | 2023-06-14 |
| PT4021929T (pt) | 2023-06-21 |
| SI4021929T1 (sl) | 2023-09-29 |
| ES2950137T3 (es) | 2023-10-05 |
| DK4021929T5 (da) | 2024-07-29 |
| MX2023002182A (es) | 2023-11-16 |
| DK4021929T3 (da) | 2023-07-10 |
| US12139520B2 (en) | 2024-11-12 |
| EP4021929B1 (en) | 2023-04-26 |
| US20250129134A1 (en) | 2025-04-24 |
| EP4021929A1 (en) | 2022-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202301635B (en) | Ham15-52 analogues with improved amylin receptor (hamy3r) potency | |
| PH12020551742A1 (en) | Gip derivatives and uses thereof | |
| MX2024009997A (es) | Composicion farmaceutica para inyeccion subcutanea que comprende una variante de hialuronidasa humana ph20 y un farmaco | |
| AP1763A (en) | Pulmonary administration of chemically modified insulin | |
| Conlon et al. | Peptides from frog skin with potential for development into agents for Type 2 diabetes therapy | |
| JOP20210089A1 (ar) | نظائر بروتين تيروسين-تيروسين وطرق لاستخدامها | |
| PH12023500004A1 (en) | Conjugated hepcidin mimetics | |
| PE20081804A1 (es) | Polipeptidos del receptor de activina variante y usos de los mismos | |
| PH12021551243A1 (en) | Oxyntomodulin peptide analog formulations | |
| MX2019013801A (es) | Compuestos de citocina inhibidora de macrofagos-1 (mic-1) y usos de estos. | |
| MY205028A (en) | Protein for treatment of inflammatory diseases | |
| MX2023002439A (es) | Composiciones immunogénicas y usos de las mismas. | |
| EP4483863A3 (en) | Liquid formulations of amylin analogues | |
| MX2025015167A (es) | Analogos con propiedades mejoradas | |
| DE602005023342D1 (en) | S (porcine reproductive und respiratory syndrome) von schweinen | |
| MX2025005176A (es) | Metodos para el tratamiento de la obesidad | |
| PH12022551985A1 (en) | Compositions and methods for delivering pharmaceutically active agents | |
| PH12020551596A1 (en) | Melanocortin receptor-specific peptide formulations and methods for gastrointestinal tract-specific delivery | |
| MX2022014455A (es) | Formulacion de anticuerpo anti-clever-1 estable. | |
| WO2022157747A3 (en) | Pharmaceutical glp peptide compositions and methods of preparation thereof | |
| MX2025009969A (es) | Compuestos analogos de hormonas peptidicas | |
| ZA202404498B (en) | Recombinant protein for sars-cov2 disease | |
| MX2024005408A (es) | Construcciones inmunogenicas y vacunas para ser utilizadas en el tratamiento profilactico y terapeutico de enfermedades causadas por sars-cov-2. | |
| MX2024006169A (es) | Formulaciones farmaceuticas que comprenden una ciclodextrina. | |
| WO2012078734A3 (en) | Polypeptide derived from calcitonin receptors and methods of use |